S-adenosylmethionine stabilizes cystathionine β-synthase and modulates redox capacity by Prudova, Anna et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Biochemistry -- Faculty Publications Biochemistry, Department of 
2006 
S-adenosylmethionine stabilizes cystathionine β-synthase and 
modulates redox capacity 
Anna Prudova 
University of Nebraska at Lincoln 
Zachary Bauman 
University of Nebraska at Lincoln 
Aaron Braun 
University of Nebraska - Lincoln 
Victor Vitvitsky 
University of Nebraska - Lincoln 
Shelly C. Lu 
University of Southern California 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/biochemfacpub 
 Part of the Biochemistry, Biophysics, and Structural Biology Commons 
Prudova, Anna; Bauman, Zachary; Braun, Aaron; Vitvitsky, Victor; Lu, Shelly C.; and Banerjee, Ruma, "S-
adenosylmethionine stabilizes cystathionine β-synthase and modulates redox capacity" (2006). 
Biochemistry -- Faculty Publications. 64. 
https://digitalcommons.unl.edu/biochemfacpub/64 
This Article is brought to you for free and open access by the Biochemistry, Department of at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Biochemistry -- Faculty 
Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
Anna Prudova, Zachary Bauman, Aaron Braun, Victor Vitvitsky, Shelly C. Lu, and Ruma Banerjee 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
biochemfacpub/64 
S-adenosylmethionine stabilizes cystathionine
-synthase and modulates redox capacity
Anna Prudova*, Zachary Bauman*, Aaron Braun*, Victor Vitvitsky*, Shelly C. Lu†, and Ruma Banerjee*‡
*Redox Biology Center and Biochemistry Department, University of Nebraska, Lincoln, NE 68588-0664; and †Division of Gastroenterology and Liver Diseases,
Keck School of Medicine, University of Southern California, Los Angeles, CA 90033
Edited by Rowena G. Matthews, University of Michigan, Ann Arbor, MI, and approved March 9, 2006 (received for review November 2, 2005)
The transsulfuration pathway converts homocysteine to cysteine
and represents the metabolic link between antioxidant and meth-
ylation metabolism. The first and committing step in this pathway
is catalyzed by cystathionine -synthase (CBS), which is subject to
complex regulation, including allosteric activation by the methyl
donor, S-adenosylmethionine (AdoMet). In this study, we demon-
strate that methionine restriction leads to a >10-fold decrease in
CBS protein levels, and pulse proteolysis studies reveal that bind-
ing of AdoMet stabilizes the protein against degradation by 12
kcalmol. These observations predict that under pathological con-
ditions where AdoMet levels are diminished, CBS, and therefore
glutathione levels, will be reduced. Indeed, we demonstrate this to
be the case in a mouse model for spontaneous steatohepatitis in
which the gene for the MAT1A isoenzyme encoding AdoMet
synthetase has been disrupted, and in human hepatocellular car-
cinoma, where MAT1A is silenced. Furthermore, diminished CBS
levels are associated with reduced cell viability in hepatoma cells
challenged with tert-butyl hydroperoxide. This study uncovers a
mechanism by which CBS is allosterically activated by AdoMet
under normal conditions but is destabilized under pathological
conditions, for redirecting the metabolic flux toward methionine
conservation. A mechanistic basis for the coordinate changes in
redox and methylation metabolism that are a hallmark of several
complex diseases is explained by these observations.
glutathione  liver disease
Cellular methylation and antioxidant metabolism are linkedby the transsulfuration pathway, which converts the methi-
onine cycle intermediate, homocysteine, to cysteine, the limiting
reagent in glutathione synthesis. The balance between conserv-
ing methionine via transmethylation under conditions of methi-
onine restriction and committing it to transsulfuration under
conditions of plenty is regulated at two key control points,
methionine adenosyltransferase (MAT) and cystathionine
-synthase (CBS) (Fig. 1). Aberrations in methylation and redox
homeostasis are common to a number of chronic diseases
including pathologies of the liver. In alcoholic liver disease and
in hepatocellular carcinoma an increase in markers of oxidative
stress is observed (1, 2). Furthermore, there is a switch in the
expression of MAT genes from MAT1A to MAT2A in liver
cancer, which correlates with lower S-adenosylmethionine
(AdoMet) levels (3).
Under normal conditions, coordinate regulation of methyl-
ation and antioxidant metabolism is achieved by the allosteric
activation of CBS by AdoMet (Fig. 1). AdoMet is a V-type
allosteric effector that increases CBS activity 2- to 3-fold (4, 5).
Under conditions of plenty, methionine is directed toward
cysteine synthesis via the transsulfuration pathway for use in
glutathione and other cellular functions or directed toward
catabolism. Cysteine is the limiting reagent in glutathione syn-
thesis and in liver;50% of the cysteine in glutathione is derived
from methionine via the transsulfuration pathway (6–8). Con-
versely, it is expected that when methionine levels are low, flux
through the transsulfuration pathway is down-regulated to con-
serve the amino acid backbone in the methionine cycle (9).
In this study, we discovered that under conditions of methi-
onine restriction, CBS protein levels are diminished 10-fold.
This led us to uncover a mechanism by which a reduction in the
methyl donor, AdoMet, leads to destabilization of CBS and, in
turn, to a reduction in antioxidant capacity via glutathione. We
show that under pathological conditions with reduced AdoMet
levels, namely human hepatocellular carcinoma and a mouse
model for chronic steatohepatitis, CBS levels are diminished.
This decrease in CBS levels correlates with reduced glutathione
that is, in turn, associated with increased vulnerability to oxida-
tive stress. Posttranslational regulation of CBS stability by
AdoMet provides a mechanism for achieving coordinate changes
in cellular methylation and antioxidant status that is observed in
a number of disease states.
Results and Discussion
Methionine Restriction Reduces CBS Protein Levels. Many carcino-
mas demonstrate a methionine-dependent phenotype and are
unable to grow upon substitution of methionine in the growth
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Fig. 1. Methionine metabolism in mammals. CBS, MS, CGL, PPG, and MAT refer
to cystathionine -synthase, methionine synthase, -cystathionase, propargylg-
lycine, and methionine adenosyltransferase, respectively. The inhibitors used to
block specific enzymes are indicated. AdoHcy, S-adenosylhomocysteine.








medium by homocysteine and folic acid, substrates of the
methionine synthase reaction (10). While examining whether a
link, if any, exists between methionine dependence of many
carcinomas and changes in antioxidant capacity, we discovered
that replacement of methionine (Met) by homocysteine
(MetHcy) in folate-replete medium resulted in a marked
time-dependent decrease in CBS levels in the human hepatoma
cell lines, SkHep-1 (Fig. 2A). This effect was reversible, and
addition of methionine to cells grown in MetHcy medium
resulted in restoration of CBS to levels observed in Met
medium, albeit with faster kinetics (Fig. 2B). CBS levels in cells
grown in MetHcy were identical to those in Met medium
(data not shown), indicating that the absence of methionine
rather than the presence of homocysteine was responsible for the
observed change in CBS levels.
AdoMet Signals Methionine Restriction. To distinguish between the
possibilities that methionine itself versus a downstream metab-
olite signals a change in methionine status, we used inhibitors of
pathway enzymes (Fig. 1) in combination with rescue strategies
(Fig. 2C). Inhibition of MAT by cycloleucine resulted in lower
CBS levels versus untreated controls when cells were transferred
from MetHcy to Met medium. The other inhibitors shown
in Fig. 1 failed to inhibit restoration of CBS levels in response to
methionine provision to cells grown inMetHcymedium (data
not shown). These results suggest that AdoMet rather than
methionine signals a change in cellular methionine availability
and regulates CBS levels. Consistent with this hypothesis, the
effect of methionine restriction on CBS levels was attenuated by
provision of AdoMet (Fig. 2D). Intracellular AdoMet concen-
trations were found to decrease 14-fold from 5.4  0.4
nmolmg1 protein (n  8) in cells grown in Met medium to
0.37  0.06 nmolmg1 protein (n  7) in MetHcy medium.
The rapid induction of CBS levels by substitution of MetHcy
with Metmedium (Fig. 2) was accompanied by an overshoot in
AdoMet concentrations after 24 h [19.1  2.6 nmolmg1 of
protein (n  4)] and returned to steady-state levels at 48 h.
CBS Is Repressed in MAT1A Knockout Mice with High Methionine and
Low AdoMet. To more clearly interrogate the role of AdoMet in
regulating CBS levels, we used the transgenic murine model in
which the gene forMAT1A (encoding the MATIIII isoenzyme)
is disrupted (11). This knockout induces expression of the
MATII isoenzyme in liver with a consequent lowering of hepatic
AdoMet and glutathione levels by 4- and 2.5-fold, respectively,
and results in an 8-fold increase in plasma methionine levels
(11). Chronic hepatic insufficiency of AdoMet in the MAT1A
knockout mice predisposes them to spontaneous steatohepatitis
and hepatocellular carcinoma (11, 12). The MAT1A knockout
mice serve as an ideal model to test the effect of reduced
AdoMet in a background of high methionine on CBS expression.
Western analysis revealed that CBS levels were an excellent
predictor of genotype and that steady-state CBS levels and
activity were diminished 87  5% (n  3) and 78  4% (n  5),
respectively (Fig. 3A and B), whereas Northern analysis revealed
no change in CBS mRNA levels (data not shown).
CBS Is Reduced in Human Liver Cancer. Hepatocellular carcinomas
are characterized by a switch in expression of the MAT isoen-
zyme from MATIIII associated with high AdoMet and a
differentiated phenotype, to MATII associated with lower
AdoMet and a dedifferentiated phenotype (3). Hepatic cirrhosis
is the most common precursor to development of hepatocellular
carcinoma and is characterized by increased oxidative stress and
decreased glutathione (2). Based on our observations, we hy-
pothesized that down-regulation of CBS may be correlated with
the spontaneous oxidative stress and liver injury associated with
this pathology. Indeed, a substantial decrease in CBS levels and
activity were observed when histologically established noncan-
cerous versus cancerous tissues in the same patient obtained
from liver biopsy samples were compared (Fig. 3 C and D).
Fig. 2. Regulation of CBS by methionine status. (A) SkHep-1 cells were grown
for 7 days in MEM containing 100 M methionine and switched to MetHcy
medium containing 200M DL-homocysteine. CBS and actin (an equal loading
control) were detected in cell extracts by Western analysis as described under
Methods and are representative of four independent experiments. A similar
response was observed in the human hepatoma cell line HepG2 and the
transformed monkey kidney cell line COS-1 (not shown). (B) Reversible regu-
lation of CBS by methionine. Change in CBS concentration normalized to the
density of actin in each lane was plotted as a function of time in cells switched
from Met to MetHcy medium or vice versa. Before switching to Met
medium, SKHep-1 cells were cultured for 7 days in MetHcy medium. Data
are the average of four independent experiments. (C) AdoMet signals changes
in methionine status. SkHep-1 cells were grown in MetHcy medium for 7
days, CBS expression was induced by transferring cells to Met medium with
or without 20 mM cycloleucine (CL), and CBS levels were assessed by Western
analysis 0, 24, and 48 h later. Data are representative of at least three
experiments performed in duplicate. (D) AdoMet or its structural analog,
AdoEt, can induce CBS under conditions of methionine restriction. SkHep-1
cells grown for 7 days in MetHcy medium were transferred to the same
medium supplemented with either 100M methionine or 500M AdoMet or
500 M AdoEt. CBS levels were assessed by Western blot analysis 72 h later.
Data are representative of two experiments performed in duplicate.
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Glutathione levels were decreased from 5.7 to 3.2 mol(g of
tissue)1 in control versus malignant tissues in one liver biopsy
sample and from 4.1 to 0.7 mol(g of tissue)1 in another.
Stability of CBS Is Decreased Under Conditions of Methionine Restric-
tion. In principle, a decrease in CBS levels in response to
diminished cellular methylation capacity could be effected at
multiple levels and various modes of gene regulation by AdoMet
are known. In bacteria, AdoMet binds to RNA riboswitches and
regulates genes involved in sulfur metabolism (13). In Arabidop-
sis thaliana, stability of the cystathionine -synthase mRNA is
negatively regulated by AdoMet (14), and in HepG2 cells,
methionine withdrawal results in an AdoMet-dependent in-
crease in MATII expression by stabilization of its mRNA (15).
We excluded an effect of AdoMet on transcription (by Northern
analysis and reporter assays using the1b CBS promoter, which
is most commonly used in liver) and translation (by in vitro
transcriptiontranslation and polysome analysis) (data not
shown). In contrast, pulse–chase studies revealed a marked
decrease in the t1/2 of CBS from 49  4 h in cells grown in Met
to 18  2 h in cells grown in MetHcy medium (data not
shown).§ The relatively long half-life of CBS measured in these
experiments is consistent with the slow kinetics of its disappear-
ance upon methionine restriction (Fig. 2).
Binding of AdoMet Stabilizes CBS. AdoMet is an allosteric effector
of CBS and binds to the regulatory domain (16), which contains
a tandem repeat of ‘‘CBS domains,’’ a secondary structure motif
that binds various adenine nucleotides and is believed to play a
role in energy sensing (17). AdoMet binding increases CBS
activity 2- to 3-fold (5). To distinguish between a structural
versus a chemical role (i.e., via methyl transfer) for AdoMet in
modulating stability of CBS, the ability of the structural analog,
S-adenosyl-L-ethionine (AdoEt), to induce CBS in MetHcy-
grown cells was tested (Fig. 2D). AdoEt activates CBS in vitro (4)
and was as effective as AdoMet in inducing CBS levels in vivo,
suggesting that the stabilizing effect of AdoMet on CBS in cells
is associated with binding rather than methyl transfer to CBS or
to some other target. To further test whether AdoMet binding
enhances CBS stability in vivo, we used the pathogenic D444N
variant of CBS, which is unresponsive to the allosteric effects of
AdoMet (18, 19). It exists predominantly in an activated con-
formation in the absence of AdoMet, mimicking that achieved by
wild-type enzyme in the presence of AdoMet (20). Our hypoth-
esis that AdoMet binding stabilizes CBS leads to the prediction
that the D444N mutant would be less responsive to methionine
restriction. Indeed, in a cell line homozygous for the D444N
allele, only a 2-fold decrease in CBS levels was observed in cells
grown in MetHcy versus Met medium (Fig. 3E) whereas
CBS levels decreased 10-fold in normal fibroblast cells grown
in MetHcy versus Met medium (data not shown). Methio-
nine synthase levels did not change and served as an equal
loading control.
The above results provide strong evidence that AdoMet not
only activates but also enhances stability of CBS. Next, we used
pulse proteolysis (21) to quantify the effect of AdoMet on CBS
stability (Fig. 4 A–C). In the presence of AdoMet, the Cm value
(i.e., the concentration of urea required to unfold half the CBS)
increased from 2.9  0.1 M to 4.6  0.02 M. The global stability
of CBS, G°unf, increased from 20.6 kcalmol1 in the absence of
AdoMet to 33 kcalmol1 in its presence. Hence, binding of
AdoMet provides significant stabilization to CBS.
CBS Down-Regulation Affects Viability Under Oxidative Stress Condi-
tions.The effect of CBS down-regulation on transsulfuration flux
was measured in SKHep-1 cells as a time-dependent increase in
cystathionine levels in cells treated with propargylglycine, an
inhibitor of -cystathionase. The flux was found to be 220  22
and 118  17 mol of cystathionine(liter of cells)1h1 in cells
grown in Met versus MetHcymedia, respectively. The 2-fold
decrease in flux through CBS was associated with the 10-fold
difference in protein levels in cells grown in Met versus
MetHcy media. This apparent discrepancy in the magnitude
of CBS levels and flux through it suggests that CBS is not fully
rate limiting in converting methionine to cystathionine. This is
consistent with the 2.5-fold decrease in glutathione levels in
MAT1A knockout mice (11) in which CBS levels were found to
be decreased 5-fold. To assess the physiological effect of CBS
§The doubling time of SK-Hep1 cells in Met medium is 3 days and could lead to an
underestimation of the t1/2 of CBS under these conditions. In contrast, growth of SK-Hep1
cells stalls in MetHcy medium (without a visible loss in cell density) as reported previ-
ously for other cancer cell lines (28).
Fig. 3. CBS expression in liver disease states. (A) Hepatic CBS levels were
determined by Western blot analysis in wild type () and MAT1A knockout
() mice. Protein concentration was determined by using the Bradford
assay, and equal loading of samples in each lane was ensured by monitoring
actin levels. (B) CBS-specific activity was determined by the ninhydrin assay (8)
in wild-type (black bars) and MAT1A knockout (gray bars) mouse livers. (C)
Hepatic CBS levels were determined by Western blot analysis in control (1C and
2C) and cancerous (1HC and 2HC) biopsied liver tissue from two patients with
hepatocellular carcinoma. (D) CBS-specific activity was determined by the
ninhydrin assay in normal (black bars) and cancerous (gray bars) liver tissue.
Samples 1C and 1HC and 2C and 2HC are derived from normal and hepato-
cellular cancer tissue from the same patient, respectively. (E) Effect of methi-
onine availability on CBS expression in fibroblasts (F4875) homozygous for the
D444N mutation in CBS. The patient fibroblast cell line was grown for 7 days
in either Met or MetHcymedium. Levels of CBS, methionine synthase, and
actin were monitored by Western analysis. Data are representative of three
independent experiments performed in duplicate.








regulation on antioxidant capacity, the effect of tert-butyl hy-
droperoxide on cells containing high and low CBS levels was
determined (Fig. 5). Cells grown in Met medium were signif-
icantly more resistant to the oxidative challenge than were cells
grown in MetHcy medium that had low CBS levels. This
difference in viability was partially negated by provision of
N-acetylcysteine, a cysteine precursor that can bypass intracel-
lular cysteine deficiency imposed by reduced transsulfuration
flux.
Interestingly, AdoMet has been suggested as a therapeutic
agent for chemoprevention and treatment of hepatic cancer (22)
and is already being used in clinical trials for the treatment of
cirrhosis and alcoholic liver disease, chronic conditions charac-
terized by decreased glutathione and increased oxidative stress.
Indeed, it has been reported that long-term treatment of alco-
holic liver cirrhosis patients with AdoMet may improve survival
or delay liver transplantation (23). Our results suggest that in
addition to correcting the methylation status, AdoMet supple-
mentation would enhance transsulfuration capacity by stabiliz-
ing CBS, and that an alternative strategy, i.e., administration of
N-acetylcysteine, could bypass the block by acting downstream of
it. It is interesting to note that oral supplementation with
different cysteine-rich whey protein formulas is already used to
increase glutathione levels in patients with cystic fibrosis (24) or
HIV infection (25) and that the therapy appears to be well
tolerated.
In summary, our studies suggest a mechanistic basis for the
coordinate changes in methylation and antioxidant capacity that
is observed in many diseases. Stabilization of CBS, which
catalyzes the committing step in the bridging transsulfuration
pathway, by AdoMet, a signal of cellular methylation status,
represents a strategy whereby an allosteric effector enhances
catalytic activity while also increasing the t1/2 of the protein. The
relevance of this mode of regulation to metabolic changes
observed in transformed liver cells, in a mouse model susceptible
to liver injury and in human liver cancer, suggests therapeutic
strategies that may be effective in diminishing the enhanced
oxidant burden associated with reduced transsulfuration flux in
these conditions.
Methods
MAT1A Knockout Mice and Human Liver Samples.MAT1A knockout
mice were maintained at the University of Southern California,
and livers were obtained as described in ref. 11. Cancerous liver
tissue was obtained from two patients undergoing surgical
resection for primary hepatocellular carcinoma. Noncancerous
liver tissue included in the resected specimen was used as the
control sample. Written informed consent was obtained from
each patient. These tissues were immediately frozen in liquid
nitrogen for subsequent measurement of glutathione and pro-
teins as described below. The study protocol conformed to the
ethical guidelines of the 1975 Declaration of Helsinki as re-
f lected in a priori approval by the University of Southern
California School of Medicine’s human research review
committee.
Cell Culture and Western Blot Analysis. Transformed cells
(SkHep-1, COS-1, and HepG2) were grown in Eagle’s minimum
essential medium containing methionine (Met) or lacking
methionine but containing 200 M DL-homocysteine
(MetHcy) supplemented with 10% dialyzed FBS and an
antibiotic–antimycotic mixture (Invitrogen) of 100 unitsml
penicillin G sodium, 100 gml streptomycin sulfate, and 0.25
gml amphotericin B. Both media contained cystine and folic
acid at concentrations of 100 M and 2.3 M, respectively.
Primary fibroblast cultures were grown in the same media but
lacking amphotericin B. Cultures were maintained at 37°C in a
5% CO2 atmosphere. Inhibitors or other supplements were
added to the media at the concentrations indicated in the figure
legends. Cells were harvested by trypsinization, washed twice
with ice-cold PBS, and, after centrifugation, resuspended in an
equal volume of lysis buffer [0.1 M sodium phosphate (pH 7.4),
Fig. 4. AdoMet stabilizes CBS. (A and B) Proteolytic digestion of CBS in the
absence (A) or presence (B) of 300 M AdoMet by pulse proteolysis as described
in Methods. The first lane in each gel represents molecular-weight markers. (C)
Dependence of the fraction of folded protein (ffold) on the denaturant concen-
tration in the absence (open squares) and presence (filled squares) of 300 M
AdoMet. Data are averages of four independent experiments.
Fig. 5. The effect of diminished CBS on cell viability at increasing concen-
trations of tert-butyl hydroperoxide in cells grown in the Met (filled circles),
MetHcy (filled triangles), or MetHcy plus N-acetylcysteine (NAC) (open
triangles) medium. Viability is represented as a percentage of viable cells in
untreated controls, and each data point is the average of three to six inde-
pendent determinations.
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containing 0.1% Triton X-100, 10 lml protease inhibitor
mixture (Sigma), 25 gml tosyllysine chloromethyl ketone, 25
gml phenylmethylsulfonyl f luoride, 27 gml aprotinin, and
10 gml leupeptin], placed on ice for 20 min, and stored at
80°C until further use. The lysate was centrifuged at 4°C for 20
min at 14,000  g, and the protein concentration in the
supernatant was determined by the Bradford assay (Bio-Rad).
After electrophoresis on a 10% polyacrylamide gel and transfer
to a PVDF membrane, methionine synthase, CBS, and actin
levels were determined by using the respective primary and
secondary antibodies and detected by using the chemilumines-
cent horseradish peroxidase system (Sigma) as described in ref.
8. The intensities of protein and nucleic acid bands were
quantified by densitometry with QUANTITY ONE software (Bio-
Rad). For Western analysis, the CBS signal in each lane was first
normalized to actin in the same lane before comparison with
control values.
CBS Activity, Metabolite Levels, and FluxMeasurements.CBS activity
was measured by using the ninhydrin assay as described in ref. 8.
For f lux measurements, cells were incubated in Met or
MetHcy medium for 7 days with the final medium change
being performed 1 day before initiation of the experiment. One
hour before the experiment, cells were transferred to fresh Met
medium so that flux measurements were performed at the same
concentration of methionine to reflect a difference in CBS level
and function, rather than methionine availability. Western blots
were performed to establish that no change in CBS levels
occurred during the experimental time frame. Flux measure-
ments were conducted as described in ref. 7. Briefly, experiments
were initiated by addition of propargylglycine (2.5 mM final
concentration), and time points were collected after 0-, 3-, and
7-h incubation periods. Flux was expressed as the amount of
cystathionine, molh1(liter of cells)1. Metabolite levels (glu-
tathione and AdoMet) were determined as described in ref. 26.
All values reported in this study represent the mean  SEM.
In Vivo Pulse–Chase Analysis. SkHep-1 cells were grown for 3 days
in 60-mm dishes in either Met or MetHcy medium. After a
1-h incubation in leucine-deficient medium, cells were pulsed for
10 h with 200 Ci of L-[4,5-3H]leucine (Amersham Pharmacia;
specific activity 162 Cimmol; 1 Ci 37 GBq) in 1 ml of leucine-
and methionine-deficient medium that was supplemented with
either 100 M L-methionine or 200 M DL-homocysteine,
respectively. After 10 h, cells were washed with 2  2 ml of PBS
to remove unincorporated radioactivity and placed in chase
medium containing 1 mM leucine and either methionine or
homocysteine. A batch of cells from each condition was collected
after 0, 12, 24, 36, and 48 h of incubation in chase medium and
washed twice with ice-cold PBS, harvested with a cell scraper in
the presence of 600 l of lysis buffer, and frozen at 80°C until
further analysis. For CBS immunoprecipitation, the lysates were
thawed on ice and centrifuged at 14,000  g for 15 min at 4°C.
Lysates containing equal amounts of total protein (as judged by
Bradford; Bio-Rad) were adjusted to a 600-l volume each and
then incubated by using 20 l of agarose-linked anti-chicken IgY
antibody (Aves Labs). After preclearing, the supernatants were
incubated with 2.5 ng of purified anti-CBS antibody (developed
in chicken by using purified recombinant human CBS) for 2 h at
4°C with vigorous shaking, followed by a 2-h incubation with 20
l of agarose-linked anti-chicken IgY antibody. The beads were
collected by centrifugation and washed according to the manu-
facturer’s recommendations by using the Immunoprecipitation
kit (Sigma). To elute the protein, the beads were incubated with
50 l of Laemmli sample buffer for 15 min at 95–100°C and spun
down, and the clear supernatant was collected, divided into two
portions, and separated on two SDS gels. One gel was incubated
for 30 min in a fixing solution containing 10% (volvol) acetic
acid and 30% methanol (volvol), then impregnated with the
EN3HANCE solution (PerkinElmer) for 30 min and dried at
70°C. The dried gel was exposed to BioMax film (Kodak) at
80°C for 1–2 months. The autoradiography signal was normal-
ized to the amount of CBS in each sample, as judged by
densitometric analysis of the Western blot performed with the
second gel. The initial experiments established that the radio-
activity associated with CBS represented 90% of the total
signal observed in the autoradiogram. Therefore, as a time-
saving strategy, additional samples were analyzed for tritium
content directly by using a liquid scintillation counter, and the
dpm were normalized for CBS levels in each sample as judged
by Western blot analysis.
In Vitro Pulse Proteolysis. Pulse proteolysis of CBS was performed
as described in ref. 21. Briefly, thermolysin (0.20 mgml from
Bacillus thermoproteolyticus rokko; Sigma) was used to digest
purified recombinant human CBS (0.50 mgml) at 25°C that had
been equilibrated overnight at 4°C in 20mMTrisHCl buffer (pH
8.3) containing 10 mM CaCl2, 50 mM NaCl, and urea (0–7 M).
To monitor CBS stability in the presence of AdoMet, the protein
was first preincubated with 300 M AdoMet for 30 min on ice
and then exposed to a urea solution containing 300 MAdoMet.
The reaction was initiated by the addition of a 25 stock solution
of thermolysin in 1.25 M NaCl and 0.25 M CaCl2. After 1 min,
the reaction was quenched by the addition of 50 mM EDTA (pH
8.0) to a final concentration of 12.5 mM. Samples were mixed
with Laemmli buffer, boiled for 5 min, separated on a 10%
SDSPAGE gel, and stained with Coomassie blue solution. The
gels were scanned and CBS band intensities were quantified by
using QUANTITY ONE image analysis software. The global sta-
bility of a protein, G°unf, was calculated by multiplying the Cm
by the m-value (the denaturant dependence of G°unf). The
m-value of CBS was estimated as described in ref. 21 by
multiplying the number of residues by 0.013 and found to be
7.2 kcal(molM).
Cell Viability Studies. SkHep-1 cells were grown for 7 days in six-well
plates in Met or MetHcy medium. Immediately before the
experiment, the medium was replaced with a fresh 2-ml aliquot of
Met medium, to which freshly prepared tert-butyl hydroperoxide
in ethanol was added. Controls received the equivalent volume of
vehicle only.N-acetylcysteine was added to a final concentration of
200 M 3 h before peroxide addition to test its effect on viability
of MetHcy-grown cells. After a 10-h incubation with peroxide,
the viability of cells was assessed by using the 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazolium bromide dye method (27) and ex-
pressed as a percentage of untreated controls.
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